Lead Product(s): TRS01,Adapalene
Therapeutic Area: Ophthalmology Product Name: TRS01
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Company received important feedback on its trial design and program for its TRS01 Phase 3 program in uveitis, including feedback on its nonclinical and CMC plans supporting submission of a New Drug Application (NDA) in the U.S.
Lead Product(s): CSF-1
Therapeutic Area: Ophthalmology Product Name: PresbiDrops
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Bluestem Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 10, 2020
Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia symptoms through completion of its Phase 3 clinical trials.